CellaVision AB (CellaVision AB) 3-Year EBITDA Growth Rate : 12.20% (As of Mar. 2024)

View and export this data going back to 2010. Start your Free Trial

What is CellaVision AB 3-Year EBITDA Growth Rate?

CellaVision AB's EBITDA per Share for the three months ended in Mar. 2024 was $0.16.

During the past 12 months, CellaVision AB's average EBITDA Per Share Growth Rate was 8.60% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 12.20% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 11.30% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 18.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of CellaVision AB was 59.90% per year. The lowest was 8.20% per year. And the median was 21.60% per year.

Competitive Comparison of CellaVision AB's 3-Year EBITDA Growth Rate

For the Medical Devices subindustry, CellaVision AB's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CellaVision AB's 3-Year EBITDA Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, CellaVision AB's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where CellaVision AB's 3-Year EBITDA Growth Rate falls into.

CellaVision AB 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

CellaVision AB (OTCPK:CLVSF) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

CellaVision AB 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of CellaVision AB's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

CellaVision AB (CellaVision AB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CellaVision AB (OTCPK:CLVSF) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

CEVI:Sweden 0MR5:UK C26:Germany

Address

Mobilvagen 12, Lund, SWE, 22362

Website

https://www.cellavision.com

CellaVision AB is engaged in the business of supplying digital solutions for blood and body fluid analysis. Its solutions are based on digital image analysis technology, artificial intelligence, and information technology. The firm's product portfolio consists of CellaVision peripheral blood application, CellaVision advanced RBC application, and CellaVision remote review software. Its customers include mainly large hospital laboratories and commercial laboratories in North America, Europe and China, and Japan. The company derives the majority of its revenue from the sale of analyzers.

CellaVision AB (CellaVision AB) Headlines

From GuruFocus

3 Scandinavian Companies With Strong Margin Growth

By James Li James Li • 12-01-2020